Earnings summaries and quarterly performance for Option Care Health.
Executive leadership at Option Care Health.
John C. Rademacher
Detailed
President and Chief Executive Officer
CEO
CL
Christopher L. Grashoff
Detailed
Chief Growth Officer
CG
Collin G. Smyser
Detailed
General Counsel and Corporate Secretary
FA
Femi Adewunmi, M.D.
Detailed
Chief Medical Officer
LW
Luke Whitworth
Detailed
Chief Operating Officer
MS
Meenal Sethna
Detailed
Chief Financial Officer
MB
Michael Bavaro
Detailed
Chief Human Resources Officer
Board of directors at Option Care Health.
BW
Barbara W. Bodem
Detailed
Director
DW
David W. Golding
Detailed
Director
ED
Elizabeth D. Bierbower
Detailed
Director
EQ
Elizabeth Q. Betten
Detailed
Director
EK
Eric K. Brandt
Detailed
Director
HM
Harry M. Jansen Kraemer, Jr.
Detailed
Independent Board Chair
ND
Natasha Deckmann, M.D.
Detailed
Director
NL
Norman L. Wright
Detailed
Director
RC
R. Carter Pate
Detailed
Director
TP
Timothy P. Sullivan
Detailed
Director
Research analysts who have asked questions during Option Care Health earnings calls.
CD
Constantine Davides
Citizens JMP
4 questions for OPCH
Also covers: ADUS, AMN, CCRN +9 more
JG
Joanna Gajuk
Bank of America
4 questions for OPCH
Also covers: ACHC, ADUS, AGL +21 more
PC
Pito Chickering
Deutsche Bank
4 questions for OPCH
Also covers: ACHC, AHCO, AVAH +18 more
Brian Tanquilut
Jefferies
3 questions for OPCH
Also covers: ACHC, ADUS, AHCO +29 more
DM
David Macdonald
Truist Securities
3 questions for OPCH
Also covers: AVAH, ENSG, GRDN +3 more
LG
Lisa Gill
JPMorgan Chase & Co.
3 questions for OPCH
Also covers: AGL, CAH, CI +13 more
ML
Matthew Larew
William Blair & Company
3 questions for OPCH
Also covers: AMED, ATR, DNA +10 more
AR
A.J. Rice
UBS Group AG
2 questions for OPCH
Also covers: ACHC, AMED, AMN +20 more
SC
Sarah Conrad
Goldman Sachs
2 questions for OPCH
JS
Jack Slevin
Jefferies Financial Group Inc.
1 question for OPCH
Also covers: AGL, AMN, ASTH +8 more
JP
Jamie Perse
The Goldman Sachs Group, Inc.
1 question for OPCH
Also covers: BTSG, CON, DOCS +8 more
Recent press releases and 8-K filings for OPCH.
Option Care Health Provides Preliminary 2024 Results and 2026 Guidance
OPCH
Guidance Update
Revenue Acceleration/Inflection
Share Buyback
- Option Care Health reported preliminary unaudited 2024 results, including approximately 13% revenue growth, 6% Adjusted EBITDA growth, and 10% Adjusted EPS growth at the midpoint, surpassing prior guidance.
- The company issued 2026 guidance, forecasting 4% revenue growth, 5% EBITDA growth, and 7% diluted EPS growth year-over-year at the midpoint.
- The 2026 guidance accounts for a 400 basis point revenue headwind and an estimated $25-$35 million EBITDA headwind from Stelara and related biosimilars, which are projected to constitute less than 1% of company revenue and gross profit in 2026.
- Strategic capital allocation for 2026 and beyond includes continued investment in the business, disciplined pursuit of adjacent and accretive M&A, and periodic share repurchases.
- The company highlighted its diversified portfolio, with no single therapy exceeding 4% of gross profit, and its extensive national network comprising over 190 locations and 750 infusion chairs.
2 days ago
Option Care Health Provides Preliminary 2025 Results and 2026 Guidance
OPCH
Guidance Update
Share Buyback
New Projects/Investments
- Option Care Health reported preliminary 2025 results, including 13% revenue growth, 6% adjusted EBITDA growth, and 10% adjusted EPS growth at the midpoint. The company served over 315,000 unique patients in 2025.
- For 2026, Option Care Health provided guidance for 4% revenue growth, 5% EBITDA growth, and 7% EPS growth at the midpoint. This guidance incorporates an estimated 400 basis point revenue headwind and a $25-$35 million gross profit/EBITDA headwind due to Stelara and related biosimilars.
- The company's capital allocation strategy prioritizes investing in the business, pursuing adjacent and accretive M&A opportunities, and conducting periodic share repurchases, with an announced expansion of its share repurchase authorization.
- Option Care Health emphasizes its national scale with local responsiveness, operating over 190 locations and 750 infusion chairs, with 96% coverage of the U.S. population through over 800 payer relationships. No single therapy represents more than 4% of the company's gross profit.
2 days ago
Option Care Health Reports Preliminary FY 2025 Results and Provides FY 2026 Guidance
OPCH
Earnings
Guidance Update
Share Buyback
- Option Care Health reported preliminary unaudited FY 2025 results including 13% revenue growth, 6% Adjusted EBITDA growth, and 10% Adjusted EPS growth.
- The company provided FY 2026 guidance projecting 4% net revenue growth, 5% Adjusted EBITDA growth, and 7% Adjusted Diluted EPS growth, incorporating a ($25M) – ($35M) headwind from Stelara and Stelara biosimilars.
- Option Care Health repurchased $307 million of shares in FY 2025 and a total of $715 million from 2021 to Q3 2025.
- The company maintains a robust balance sheet with approximately $700 million in liquidity and a 1.9x Net Debt Leverage Ratio as of Q3 2025.
2 days ago
Option Care Health Provides Preliminary 2024 Results and 2026 Guidance
OPCH
Guidance Update
M&A
Share Buyback
- Option Care Health reported preliminary unaudited 2024 results including approximately 13% revenue growth, 6% Adjusted EBITDA growth, and 10% Adjusted EPS growth at the midpoint. For 2026, the company provided guidance projecting 4% revenue growth, 5% EBITDA growth, and 7% diluted EPS growth at the midpoint, factoring in a 400 basis point revenue headwind from Stelara and related biosimilars.
- The company's capital allocation strategy prioritizes investing in the business, pursuing adjacent and accretive M&A opportunities (such as the acquisition of Intramed Plus), and executing periodic share repurchases, supported by an expanded share repurchase authorization and strong cash flow generation.
- Option Care Health served over 315,000 unique patients in 2024 and continues to leverage its national network of over 190 locations and 750 infusion chairs. The company expects higher growth in the chronic care segment in 2026 and is optimistic about legislative efforts like site neutrality that promote lower-cost home infusion care.
2 days ago
Option Care Health Announces Preliminary Q4 and Full Year 2025 Results and 2026 Guidance
OPCH
Earnings
Guidance Update
Share Buyback
- Option Care Health announced preliminary unaudited net revenue for Q4 2025 is expected to be between $1.46 billion and $1.47 billion, and for full year 2025 between $5.645 billion and $5.655 billion.
- Preliminary unaudited adjusted diluted EPS for Q4 2025 is expected to be between $0.46 and $0.49, and for full year 2025 between $1.72 and $1.76.
- For full year 2026, the company provided preliminary financial guidance, expecting net revenue between $5.8 billion and $6.0 billion and adjusted diluted EPS between $1.82 and $1.92.
- On January 9, 2026, the Board of Directors approved an increase to the share repurchase program authorization from $500 million to $1.0 billion, following approximately $307 million in repurchases during the full year 2025.
3 days ago
Option Care Health Announces Preliminary Q4 and Full Year 2025 Results and 2026 Guidance
OPCH
Earnings
Guidance Update
Share Buyback
- Option Care Health announced preliminary unaudited financial results for Q4 2025 and Full Year 2025, along with preliminary financial guidance for Full Year 2026.
- The company's Board of Directors approved an increase to its share repurchase program authorization from $500 million to $1.0 billion on January 9, 2026. Approximately $193 million of purchase capacity remained as of December 31, 2025.
| Metric | Q4 2025 | FY 2025 | FY 2026 |
|---|---|---|---|
| Net Revenue ($USD Billions) | $1.46 to $1.47 | $5.645 to $5.655 | $5.8 to $6.0 |
| GAAP Diluted EPS ($USD) | $0.37 to $0.39 | $1.27 to $1.29 | N/A |
| Adjusted Diluted EPS ($USD) | $0.46 to $0.49 | $1.72 to $1.76 | $1.82 to $1.92 |
| Adjusted EBITDA ($USD Millions) | $123.7 to $127.7 | $469.0 to $473.0 | $480 to $505 |
| Cash Flow from Operations ($USD Millions) | N/A | Below $320 | N/A |
3 days ago
Option Care Health Discusses 2026 Outlook Amid Stelara Dynamics and Growth Drivers
OPCH
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Option Care Health (OPCH) targets a medium-term financial algorithm of high single-digit revenue growth, low double-digit EBITDA growth, and even better earnings per share growth.
- The company expects to deliver solid growth in revenue, EBITDA, and EPS in 2026, despite navigating a $70 million gross profit headwind in 2025 related to Stelara pricing dynamics and biosimilar impacts, which they have managed by raising sales and earnings guidance.
- The Stelara situation for 2026 is complex, involving multiple biosimilars, next-generation drugs, payer formulary decisions, and doctor/patient choices, with clarity expected to emerge through Q1 2026.
- While new subcutaneous formulations (e.g., Entyvio, Ocrevus, Vyvgart Hytrulo) are emerging, Option Care Health anticipates continued involvement through medical oversight, compounding, or assisting patients unable to self-administer, and notes that payers may not always reimburse more expensive options.
- Option Care Health benefits from payer interest in lower-cost care settings, positioning itself as a solution to manage specialty drug spending and drive site-of-care management initiatives.
Dec 8, 2025, 3:50 PM
Option Care Health Discusses Outlook and Stelara Dynamics at Home Care Conference
OPCH
Guidance Update
Revenue Acceleration/Inflection
- Option Care Health, the largest standalone home infusion services provider in the U.S., outlined its medium-term financial algorithm targeting high single-digit revenue growth, low double-digit EBITDA growth, and EPS growth better than EBITDA.
- The company anticipates a $60-$70 million gross profit headwind in 2025 due to Stelara pricing dynamics and biosimilar impacts, with the impact closer to $70 million. Despite this, they expect solid growth in revenue, EBITDA, and EPS in 2026.
- The Stelara situation is complex, involving specific patient cohorts, the IRA, and the launch of five or six biosimilars. The company is actively negotiating with multiple pharma companies and payers regarding formularies and reimbursement for 2026.
- The company views itself as a lower-cost solution for payers, driving long-term growth, and states that PBM reform is not expected to significantly impact its business.
Dec 8, 2025, 3:50 PM
Option Care Health Discusses Growth Outlook, STELARA Headwinds, and Future Dynamics at Home Care Conference
OPCH
Guidance Update
New Projects/Investments
Demand Weakening
- Option Care Health (OPCH) projects medium-term growth with revenue in the high single-digits, EBITDA in low double-digits, and EPS growing "a bit better than EBITDA".
- The company expects to grow revenue, earnings, and EPS in 2026, though it may not fully align with the medium-term growth algorithm.
- OPCH navigated a $60 million-$70 million gross profit headwind in 2025 related to STELARA pricing dynamics and biosimilar impact, managing to raise guidance on sales and earnings.
- The STELARA situation for 2026 is complex, involving ongoing discussions with multiple pharma companies for STELARA, 5-6 biosimilars, and next-gen therapies, as well as payer formularies and provider/patient decisions, with transitions expected through Q1 2026.
- Subcutaneous drug formulations and PBM reforms are not expected to significantly disrupt OPCH's business, as the company often remains involved in patient care or compounding, and its rebates are value-based with manufacturers.
Dec 8, 2025, 3:50 PM
Option Care Health Reports Strong Q3 2025 Performance and Positive Outlook
OPCH
Guidance Update
Debt Issuance
M&A
- Option Care Health reported strong Q3 2025 results with 12% top-line growth, 3.4% adjusted EBITDA growth, and 9.8% adjusted diluted EPS growth, leading to an increase in adjusted EBITDA guidance by $15 million and adjusted EPS projection by $0.06.
- The company maintains a strong financial position with 1.9 times leverage and expects to generate over $320 million of cash flow from operations in 2025, having recently refinanced its first lien debt to extend maturity to 2032 and add $50 million to its capital profile.
- Option Care Health anticipates a $60 million-$70 million headwind for 2025, at the higher end of the range, primarily due to changes in Stelara discounts and patient migration to biosimilars, which resulted in a 380 basis point headwind to chronic revenue in Q3.
- The company is focused on strategic growth through tuck-in M&A, leveraging its existing infrastructure for an advanced practitioner model, and has seen infusion suite utilization for nursing visits increase from 16% in 2021 to 34% in 2024.
Dec 2, 2025, 3:50 PM
Quarterly earnings call transcripts for Option Care Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more